Parainfluenza/respiratory syncytial virus vaccine (MedImmune)

N/A

Report date: 2022/11/17 20:00:51

Base Information

Drug NameParainfluenza/respiratory syncytial virus vaccine (MedImmune)

Drug Alias Name副流感病毒/呼吸道合胞体病毒疫苗 - MedImmuneRSV/PIV-3 vaccineMEDI-534

ClassificationVaccines > Biological material > Viral vaccineVaccines > Development/production technology > Live attenuated vaccineVaccines > Application > Prophylactic vaccine

Mechanisms of ActionImmunostimulants

TargetsNot applicable

Therapy Area/IndicationsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesSouth Africa +[9]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesMedimmune

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesMedimmune Llc

Active IndicationsN/A

Inactive IndicationsRespiratory Syncytial Virus InfectionsRespiratory Tract Infections

Other Information

ATC CodeN/A